Xiangning Huang

2.5k total citations
36 papers, 843 citations indexed

About

Xiangning Huang is a scholar working on Pulmonary and Respiratory Medicine, Molecular Medicine and Oncology. According to data from OpenAlex, Xiangning Huang has authored 36 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Medicine and 10 papers in Oncology. Recurrent topics in Xiangning Huang's work include Lung Cancer Treatments and Mutations (15 papers), Antibiotic Resistance in Bacteria (12 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Xiangning Huang is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Antibiotic Resistance in Bacteria (12 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Xiangning Huang collaborates with scholars based in China, United Kingdom and United States. Xiangning Huang's co-authors include J. Armstrong, Leanne B. Gasink, Jack D. Sobel, Florian Wagenlehner, Paul Newell, Katrina Yates, Gregory G. Stone, Hua Yu, Ying Cheng and Dan Li and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Astrophysical Journal.

In The Last Decade

Xiangning Huang

33 papers receiving 823 citations

Peers

Countries citing papers authored by Xiangning Huang

Since Specialization

Citations

This map shows the geographic impact of Xiangning Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangning Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangning Huang more than expected).

Fields of papers citing papers by Xiangning Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangning Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangning Huang. The network helps show where Xiangning Huang may publish in the future.

Co-authorship network of co-authors of Xiangning Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangning Huang. A scholar is included among the top collaborators of Xiangning Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangning Huang. Xiangning Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analysis of the Distribution Characteristics and Changes of Drug Resistance of Pathogens in Patients with Urinary Tract Infection Across Southwest China From 2019 to 2023 2025 ·Infection and Drug Resistance ·Min Zhong, Xiangning Huang, Xin Liu, Hua Yu, (unknown)	1
2	Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study 2025 ·Lung Cancer ·Marina Chiara Garassino, Yong He, Myung‐Ju Ahn, Sergey Orlov, Vanessa Potter, Terufumi Kato, Janessa Laskin, Pei Jye Voon, Thanyanan Reungwetwattana, Suresh S. Ramalingam, Yi‐Long Wu, Muna Albayaty, (unknown), Xiangning Huang, (unknown), Byoung Chul Cho	0
3	EGFR mutation testing across the osimertinib clinical program 2025 ·Lung Cancer ·(unknown), Suresh S. Ramalingam, Pasi A. Jänne, Jhanelle E. Gray, Myung‐Ju Ahn, Thomas John, Yasushi Yatabe, Xiangning Huang, Yuri Rukazenkov, (unknown), Helen Brown, Xiaocheng Li-Sucholeiki	0
4	Human microbiota-associated animal models: a review 2025 ·Frontiers in Cellular and Infection Microbiology ·Xiangning Huang, Yunfeng Yu, (unknown), (unknown), Xiaoqin Zhang, Yu Rong	1
5	Modification of carbapenemase inhibition test and comparison of its performance with NG-Test CARBA 5 for detection of carbapenemase-producing Enterobacterales 2024 ·Journal of Applied Microbiology ·Yue Wang, Xiangning Huang, (unknown), Siquan Shen, Jian Cui, Ziyong Sun, Fupin Hu, Hua Yu, Zhongju Chen	1
6	Temporal Shifts in Etiological Agents and Antibiotic Resistance Patterns of Biliary Tract Infections in Sichuan Province, China (2017–2023) 2024 ·Infection and Drug Resistance ·Yi Li, Dan Li, Xiangning Huang, (unknown), Hua Yu, Jie Zhang	1
7	In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates 2023 ·Microbiology Spectrum ·Dan Li, Hua Yu, Xiangning Huang, (unknown), (unknown)	8
8	Analysis on Bacterial Distribution and Change of Drug Resistance Rate in ICUs Across Southwest China from 2018 to 2022 2023 ·Infection and Drug Resistance ·(unknown), Xiao Wang, Xiangning Huang, Xin Liu, Lijun Huang	4
9	Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic 2023 ·Journal of Molecular Diagnostics ·Jhanelle E. Gray, Ji‐Youn Han, (unknown), Xiangning Huang, Alexander Kohlmann, Rachel Hodge, Yuri Rukazenkov, Juliann Chmielecki, Carin R. Espenschied, Martina I. Lefterova, Yi‐Long Wu, Suresh S. Ramalingam, J. Carl Barrett, Justin I. Odegaard	4
10	Klebsiella pneumoniae bacteremia mortality: a systematic review and meta-analysis 2023 ·Frontiers in Cellular and Infection Microbiology ·Dan Li, Xiangning Huang, (unknown), Hua Yu, (unknown), Yulian Li, Jie Zhang	46
11	Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study 2021 ·Targeted Oncology ·Ying Cheng, Yong He, Wěi Li, Helong Zhang, Qing Zhou, Buhai Wang, Chunling Liu, Andrew Walding, Matilde Saggese, Xiangning Huang, Minhao Fan, Jia Wang, Suresh S. Ramalingam	90
12	First Report of blaIMP–4 and blaSRT–2 Coproducing Serratia marcescens Clinical Isolate in China 2021 ·Frontiers in Microbiology ·Xiangning Huang, Siquan Shen, Qingyu Shi, Li Ding, Shi Wu, Renru Han, Xun Zhou, Hua Yu, Fupin Hu	11
13	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers 2021 ·Nature Communications ·Tereza Vaclová, Ursula Grazini, Lewis S. C. Ward, Daniel O’Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan J. Hartmaier, Kenneth S. Thress, Paul D. Smith, J. Carl Barrett, Julian Downward, Elza C. de Bruin	46
14	Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis 2021 ·Frontiers in Pharmacology ·Dan Li, Fei Fan, Hua Yu, Xiangning Huang, (unknown), (unknown), Jie Zhang	11
15	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis 2019 ·Journal of Thoracic Oncology ·Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng, Ji‐Youn Han, Sarah B. Goldberg, Alastair Greystoke, Jeffrey Crawford, Yanqiu Zhao, Xiangning Huang, Martin Johnson, Karthick Vishwanathan, James Yates, Andy Brown, Ariadna Mendoza‐Naranjo, Tony Mok	100
16	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer 2018 ·Lung Cancer ·Thomas John, Hiroaki Akamatsu, Angelo Delmonte, Wu‐Chou Su, Jong Seok Lee, Gee‐Chen Chang, Xiangning Huang, Suzanne Jenkins, Yi‐Long Wu	35
17	Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat 2017 ·Journal of Ethnopharmacology ·Jiajia Wang, Xiaofang Li, (unknown), Lijun Hu, (unknown), Xiangning Huang, Jinqing Hu, (unknown), Bin Chen, Dewei Shang, Yuguan Wen	40
18	A Simple HPLC–MS/MS Method for Determination of Tryptophan, Kynurenine and Kynurenic Acid in Human Serum and its Potential for Monitoring Antidepressant Therapy 2016 ·Journal of Analytical Toxicology ·Lijun Hu, Xiaofang Li, Jinqing Hu, Xiaojia Ni, Haoyang Lu, Jiajia Wang, Xiangning Huang, (unknown), Dewei Shang, (unknown)	66
19	Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program 2016 ·Clinical Infectious Diseases ·Florian Wagenlehner, Jack D. Sobel, Paul Newell, J. Armstrong, Xiangning Huang, Gregory G. Stone, Katrina Yates, Leanne B. Gasink	259
20	A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock 2012 ·Critical Care ·Peter E. Morris, Brian Zeno, Andrew C. Bernard, Xiangning Huang, Shampa Das, Timi Edeki, Steven G. Simonson, Gordon R. Bernard	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact